Lorraine Fitzpatrick, MD, discusses with Rheumatology Advisor updated abaloparatide results from the ACTIVE phase 3 clinical trial (Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women, ClinicalTrials.gov Identifier: NCT01343004).
Cosman F, Hattersley G, Miller P, Hu MY, Russo LAT, Riis B, Williams G, Fitzpatrick L. Abaloparatide-SC significantly reduces vertebral and nonvertebral fractures and increases bone mineral density (BMD) regardless of age, BMD T-Score, or prior fracture at baseline [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/abaloparatide-sc-significantly-reduces-vertebral-and-nonvertebral-fractures-and-increases-bone-mineral-density-bmd-regardless-of-age-bmd-t-score-or-prior-fracture-at-baseline/. Accessed November 23, 2016.
This article originally appeared on Rheumatology Advisor